Advertisement

Individual Patient Data Meta-analysis of Drug-eluting Versus Bare-metal Stents for Percutaneous Coronary Intervention in Chronic Versus Acute Coronary Syndromes

Published:September 06, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.07.035
      New-generation drug-eluting stents (DES) strongly reduce restenosis and repeat revascularization compared with bare-metal stents (BMS) for percutaneous coronary intervention. There is residual uncertainty as to whether other prognostically relevant outcomes are affected by DES versus BMS concerning initial presentation (chronic coronary syndrome [CCS] vs acute coronary syndrome [ACS]). We performed an individual patient data meta-analysis of randomized trials comparing new-generation DES versus BMS (CRD42017060520). The primary outcome was the composite of cardiac death or myocardial infarction (MI). Outcomes were examined at maximum follow-up and with a 1-year landmark. Risk estimates are expressed as hazard ratio (HR) with 95% confidence interval (CI). A total of 22,319 patients were included across 14 trials; 7,691 patients (34.5%) with CCS and 14,628 patients (65.5%) with ACS. We found evidence that new-generation DES versus BMS consistently reduced the risk of cardiac death or MI in both patients with CCS (HR 0.83, 95% CI 0.70 to 0.98, p <0.001) and ACS (HR 0.83, 95% CI 0.75 to 0.92, p <0.001) (p-interaction = 0.931). This benefit was mainly driven by a similar reduction in the risk of MI (p-interaction = 0.898) for both subsets (HRCCS 0.80, 95% CI 0.65 to 0.97; HRACS 0.79, 95% CI 0.70 to 0.89). In CCS and ACS, we found a time-dependent treatment effect, with the benefit from DES accumulating during 1-year follow-up, without offsetting effects after that. In conclusion, patients with CCS were slightly underrepresented in comparative clinical trials. Still, they benefited similarly to patients with ACS from new-generation DES instead of BMS with a sustained reduction of cardiac death or MI because of lower event rates within 1 year.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Piccolo R
        • Giustino G
        • Mehran R
        • Windecker S.
        Stable coronary artery disease: revascularisation and invasive strategies.
        Lancet. 2015; 386: 702-713
        • Pilgrim T
        • Vranckx P
        • Valgimigli M
        • Stefanini GG
        • Piccolo R
        • Rat J
        • Rothenbühler M
        • Stortecky S
        • Räber L
        • Blöchlinger S
        • Hunziker L
        • Silber S
        • Jüni P
        • Serruys PW
        • Windecker S.
        Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction.
        Am Heart J. 2016; 175: 56-65
        • Fox KAA
        • Metra M
        • Morais J
        • Atar D.
        The myth of “stable” coronary artery disease.
        Nat Rev Cardiol. 2020; 17: 9-21
        • Desai NR
        • Beckman J
        • Wiviott SD.
        When stable becomes unstable: the perils of impersonal medicine.
        Circulation. 2011; 123: 335-341
        • Valgimigli M
        • Sabaté M
        • Kaiser C
        • Brugaletta S
        • de la Torre Hernandez JM
        • Galatius S
        • Cequier A
        • Eberli F
        • de Belder A
        • Serruys PW
        • Ferrante G
        Effects of cobalt-chromium everolimus eluting stents or bare-metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis.
        BMJ. 2014; 349: g6427
        • Neumann FJ
        • Sousa-Uva M
        • Ahlsson A
        • Alfonso F
        • Banning AP
        • Benedetto U
        • Byrne RA
        • Collet JP
        • Falk V
        • Head SJ
        • Jüni P
        • Kastrati A
        • Koller A
        • Kristensen SD
        • Niebauer J
        • Richter DJ
        • Seferovic PM
        • Sibbing D
        • Stefanini GG
        • Windecker S
        • Yadav R
        • Zembala MO
        • ESC Scientific Document Group
        2018 ESC/EACTS guidelines on myocardial revascularization.
        Eur Heart J. 2019; 40 (Published correction appears in Eur Heart J 2019;40:3096): 87-165
        • Sabaté M
        • Brugaletta S
        • Cequier A
        • Iñiguez A
        • Serra A
        • Jiménez-Quevedo P
        • Mainar V
        • Campo G
        • Tespili M
        • den Heijer P
        • Bethencourt A
        • Vazquez N
        • van Es GA
        • Backx B
        • Valgimigli M
        • Serruys PW.
        Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.
        Lancet. 2016; 387: 357-366
        • Räber L
        • Yamaji K
        • Kelbæk H
        • Engstrøm T
        • Baumbach A
        • Roffi M
        • von Birgelen C
        • Taniwaki M
        • Moschovitis A
        • Zaugg S
        • Ostojic M
        • Pedrazzini G
        • Karagiannis-Voules DA
        • Lüscher TF
        • Kornowski R
        • Tüller D
        • Vukcevic V
        • Heg D
        • Windecker S.
        Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.
        Eur Heart J. 2019; 40: 1909-1919
        • Maron DJ
        • Hochman JS
        • Reynolds HR
        • Bangalore S
        • O'Brien SM
        • Boden WE
        • Chaitman BR
        • Senior R
        • López-Sendón J
        • Alexander KP
        • Lopes RD
        • Shaw LJ
        • Berger JS
        • Newman JD
        • Sidhu MS
        • Goodman SG
        • Ruzyllo W
        • Gosselin G
        • Maggioni AP
        • White HD
        • Bhargava B
        • Min JK
        • Mancini GBJ
        • Berman DS
        • Picard MH
        • Kwong RY
        • Ali ZA
        • Mark DB
        • Spertus JA
        • Krishnan MN
        • Elghamaz A
        • Moorthy N
        • Hueb WA
        • Demkow M
        • Mavromatis K
        • Bockeria O
        • Peteiro J
        • Miller TD
        • Szwed H
        • Doerr R
        • Keltai M
        • Selvanayagam JB
        • Steg PG
        • Held C
        • Kohsaka S
        • Mavromichalis S
        • Kirby R
        • Jeffries NO
        • Harrell FE
        • Rockhold FW
        • Broderick S
        • Ferguson TB
        • Williams DO
        • Harrington RA
        • Stone GW
        • Rosenberg Y
        • ISCHEMIA Research Group
        Initial invasive or conservative strategy for stable coronary disease.
        N Engl J Med. 2020; 382: 1395-1407
        • Piccolo R
        • Bonaa KH
        • Efthimiou O
        • Varenne O
        • Baldo A
        • Urban P
        • Kaiser C
        • Remkes W
        • Räber L
        • de Belder A
        • van ’t Hof AWJ
        • Stankovic G
        • Lemos PA
        • Wilsgaard T
        • Reifart J
        • Rodriguez AE
        • Ribeiro EE
        • Serruys PWJC
        • Abizaid A
        • Sabaté M
        • Byrne RA
        • de la Torre Hernandez JM
        • Wijns W
        • Jüni P
        • Windecker S
        • Valgimigli M
        • Coronary Stent Trialists’ Collaboration
        Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials.
        Lancet. 2019; 393 (Published correction appears in Lancet 2019;393:2492): 2503-2510
        • Piccolo R
        • Feres F
        • Abizaid A
        • Gilard M
        • Morice MC
        • Hong MK
        • Kim HS
        • Colombo A
        • Bhatt DL
        • Palmerini T
        • Stone GW
        • Windecker S
        • Valgimigli M.
        Risk of early adverse events after clopidogrel discontinuation in patients undergoing short-term dual antiplatelet therapy: an individual participant data analysis.
        JACC Cardiovasc Interv. 2017; 10: 1621-1630
        • Windecker S
        • Stortecky S
        • Stefanini GG
        • da Costa BR
        • Rutjes AW
        • Di Nisio M
        • Silletta MG
        • Maione A
        • Alfonso F
        • Clemmensen PM
        • Collet JP
        • Cremer J
        • Falk V
        • Filippatos G
        • Hamm C
        • Head S
        • Kappetein AP
        • Kastrati A
        • Knuuti J
        • Landmesser U
        • Laufer G
        • Neumann FJ
        • Richter D
        • Schauerte P
        • Sousa-Uva M
        • Taggart DP
        • Torracca L
        • Valgimigli M
        • Wijns W
        • Witkowski A
        • Kolh P
        • Jüni P
        Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.
        BMJ. 2014; 348 (Published correction appears in BMJ 349:g4605. daCosta, Bruno R corrected to da Costa, Bruno R]; Siletta, Maria G [corrected to Silletta, Maria G]; Juni, Peter [corrected to Jüni, Peter]]): g3859
        • Boden WE
        • O'Rourke RA
        • Teo KK
        • Hartigan PM
        • Maron DJ
        • Kostuk WJ
        • Knudtson M
        • Dada M
        • Casperson P
        • Harris CL
        • Chaitman BR
        • Shaw L
        • Gosselin G
        • Nawaz S
        • Title LM
        • Gau G
        • Blaustein AS
        • Booth DC
        • Bates ER
        • Spertus JA
        • Berman DS
        • Mancini GBJ
        • Weintraub WS
        • COURAGE Trial Research Group
        Optimal medical therapy with or without PCI for stable coronary disease.
        N Engl J Med. 2007; 356: 1503-1516
        • Mancini GB
        • Hartigan PM
        • Bates ER
        • Sedlis SP
        • Maron DJ
        • Spertus JA
        • Berman DS
        • Kostuk WJ
        • Shaw LJ
        • Weintraub WS
        • Teo KK
        • Dada M
        • Chaitman BR
        • O'Rourke RA
        • Boden WE
        COURAGE Investigators and Coordinators. Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy: observations from the COURAGE Trial.
        Circ Cardiovasc Interv. 2011; 4: 545-552
        • Xaplanteris P
        • Fournier S
        • Pijls NHJ
        • Fearon WF
        • Barbato E
        • Tonino PAL
        • Engstrøm T
        • Kääb S
        • Dambrink JH
        • Rioufol G
        • Toth GG
        • Piroth Z
        • Witt N
        • Fröbert O
        • Kala P
        • Linke A
        • Jagic N
        • Mates M
        • Mavromatis K
        • Samady H
        • Irimpen A
        • Oldroyd K
        • Campo G
        • Rothenbühler M
        • Jüni P
        • De Bruyne B
        FAME 2 Investigators. Five-year outcomes with PCI guided by fractional flow reserve.
        N Engl J Med. 2018; 379: 250-259
        • Mark DB
        • Spertus JA
        • Bigelow R
        • Anderson S
        • Daniels MR
        • Anstrom KJ
        • Baloch KN
        • Cohen DJ
        • Held C
        • Goodman SG
        • Bangalore S
        • Cyr D
        • Reynolds HR
        • Alexander KP
        • Rosenberg Y
        • Stone GW
        • Maron DJ
        • Hochman JS
        • ISCHEMIA Research Group
        Comprehensive quality-of-life outcomes with invasive versus conservative management of chronic coronary disease in ischemia.
        Circulation. 2022; 145: 1294-1307
        • Piccolo R
        • Franzone A
        • Windecker S.
        From bare metal to barely anything: an update on coronary stenting.
        Heart. 2018; 104: 533-540
        • Cassese S
        • Byrne RA
        • Schulz S
        • Hoppman P
        • Kreutzer J
        • Feuchtenberger A
        • Ibrahim T
        • Ott I
        • Fusaro M
        • Schunkert H
        • Laugwitz KL
        • Kastrati A.
        Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting.
        Eur Heart J. 2015; 36: 94-99
        • Palmerini T
        • D Della Riva
        • Biondi-Zoccai G
        • Leon MB
        • Serruys PW
        • Smits PC
        • von Birgelen C
        • Ben-Yehuda O
        • Généreux P
        • Bruno AG
        • Jenkins P
        • Stone GW
        Mortality follow nonemergent, uncomplicated target lesion revascularization after percutaneous coronary intervention: an individual patient data pooled analysis of 21 randomized trials and 32,524 patients.
        JACC Cardiovasc Interv. 2018; 11: 892-902
        • Weintraub WS
        • Spertus JA
        • Kolm P
        • Maron DJ
        • Zhang Z
        • Jurkovitz C
        • Zhang W
        • Hartigan PM
        • Lewis C
        • Veledar E
        • Bowen J
        • Dunbar SB
        • Deaton C
        • Kaufman S
        • O'Rourke RA
        • Goeree R
        • Barnett PG
        • Teo KK
        • Boden WE
        • Trial Research Group COURAGE
        • Mancini GBJ
        Effect of PCI on quality of life in patients with stable coronary disease.
        N Engl J Med. 2008; 359: 677-687
        • Fisher DJ
        • Carpenter JR
        • Morris TP
        • Freeman SC
        • Tierney JF.
        Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?.
        BMJ. 2017; 356: j573